Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi∗ZZ Genotype)
Malin Fromme,Audrey Payancé,Mattias Mandorfer,Katrine H Thorhauge,Monica Pons,Marc Miravitlles,Jan Stolk,Bart van Hoek,Guido Stirnimann,Sona Frankova,Jan Sperl,Andreas E Kremer,Barbara Burbaum,Christina Schrader,Amine Kadioglu,Michelle Walkenhaus,Carolin V Schneider,Fabienne Klebingat,Lorenz Balcar,Naomi N Kappe,Benedikt Schaefer,Joanna Chorostowska-Wynimko,Elmar Aigner,Sophie Gensluckner,Philipp Striedl,Pauline Roger,John Ryan,Suzanne Roche,Marius Vögelin,Aftab Ala,Heike Bantel,Jef Verbeek,Zoe Mariño,Michael Praktiknjo,Tom J G Gevers,Philipp A Reuken,Thomas Berg,Jacob George,Münevver Demir,Tony Bruns,Christian Trautwein,Heinz Zoller,Michael Trauner,Joan Genesca,William J Griffiths,Virginia Clark,Aleksander Krag,Alice M Turner,Noel G McElvaney,Pavel Strnad
DOI: https://doi.org/10.1053/j.gastro.2024.10.010
IF: 29.4
2024-10-15
Gastroenterology
Abstract:Background and aims: Homozygous Pi∗Z mutation in alpha-1 antitrypsin (Pi∗ZZ genotype) predisposes to pulmonary loss-of-function and hepatic gain-of-function injury. To facilitate selection into clinical trials typically targeting only 1 organ, we systematically evaluated an international, multicenter, longitudinal, Pi∗ZZ cohort to uncover natural disease course and surrogates for future liver- and lung-related endpoints. Methods: Cohort 1 recruited 737 Pi∗ZZ individuals from 25 different centers without known liver comorbidities who received a baseline clinical and laboratory assessment as well as liver stiffness measurement (LSM). A follow-up interview was performed after at least 6 months. Cohort 2 consisted of 135 Pi∗ZZ subjects without significant liver fibrosis, who received a standardized baseline and follow-up examination at least 2 years later, both including LSM. Results: During 2634 patient-years of follow-up, 39 individuals died, with liver and lung being responsible for 46% and 36% of deaths, respectively. Forty-one Pi∗ZZ subjects who developed a hepatic endpoint presented with significantly higher baseline liver fibrosis surrogates, that is, LSM (24 vs 5 kPa, P < .001) and aspartate aminotransferase-to-platelet ratio index (1.1 vs 0.3 units, P < .001). Liver-related endpoints within 5 years were most accurately predicted by LSM (area under the curve 0.95) followed by aspartate aminotransferase-to-platelet ratio index (0.92). Baseline lung parameters displayed only a moderate predictive utility for lung-related endpoints within 5 years (forced expiratory volume in the first second area under the curve 0.76). Fibrosis progression in those with no/mild fibrosis at baseline was rare and primarily seen in those with preexisting risk factors. Conclusions: Noninvasive liver fibrosis surrogates accurately stratify liver-related risks in Pi∗ZZ individuals. Our findings have direct implications for routine care and future clinical trials of Pi∗ZZ patients.